Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

P Moreau; M Attal; C Hulin; B Arnulf; K Belhadj; L Benboubker; A. Broijl; H Avet-Loiseau; Pieter Sonneveld

doi:10.1016/s0140-6736(19)31240-1

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, A. Broijl, H Avet-Loiseau, Pieter Sonneveld

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

370 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	29-38
Number of pages	10
Journal	Lancet (UK)
Volume	394
Issue number	10192
DOIs	https://doi.org/10.1016/s0140-6736(19)31240-1
Publication status	Published - 2019

Access to Document

10.1016/s0140-6736(19)31240-1

http://hdl.handle.net/1765/118204

Cite this

Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Broijl, A., Avet-Loiseau, H., & Sonneveld, P. (2019). Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet (UK), 394(10192), 29-38. https://doi.org/10.1016/s0140-6736(19)31240-1

Moreau, P ; Attal, M ; Hulin, C ; Arnulf, B ; Belhadj, K ; Benboubker, L ; Broijl, A. ; Avet-Loiseau, H ; Sonneveld, Pieter. / Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. In: Lancet (UK). 2019 ; Vol. 394, No. 10192. pp. 29-38.

@article{5a645cc6f064487a9e927169dd5f0028,

title = "Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study",

author = "P Moreau and M Attal and C Hulin and B Arnulf and K Belhadj and L Benboubker and A. Broijl and H Avet-Loiseau and Pieter Sonneveld",

year = "2019",

doi = "10.1016/s0140-6736(19)31240-1",

language = "Undefined/Unknown",

volume = "394",

pages = "29--38",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Ltd.",

number = "10192",

}

Moreau, P, Attal, M, Hulin, C, Arnulf, B, Belhadj, K, Benboubker, L, Broijl, A, Avet-Loiseau, H & Sonneveld, P 2019, 'Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study', Lancet (UK), vol. 394, no. 10192, pp. 29-38. https://doi.org/10.1016/s0140-6736(19)31240-1

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. / Moreau, P; Attal, M; Hulin, C; Arnulf, B; Belhadj, K; Benboubker, L; Broijl, A.; Avet-Loiseau, H; Sonneveld, Pieter.

In: Lancet (UK), Vol. 394, No. 10192, 2019, p. 29-38.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

AU - Moreau, P

AU - Attal, M

AU - Hulin, C

AU - Arnulf, B

AU - Belhadj, K

AU - Benboubker, L

AU - Broijl, A.

AU - Avet-Loiseau, H

AU - Sonneveld, Pieter

PY - 2019

Y1 - 2019

U2 - 10.1016/s0140-6736(19)31240-1

DO - 10.1016/s0140-6736(19)31240-1

M3 - Article

VL - 394

SP - 29

EP - 38

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10192

ER -